Financings ramped up dramatically in 2015 with $68 billion collected, but the amount does not touch biopharma investment in the last two years. The industry has raised $113 billion in 2021, down from the $134.5 billion full year 2020 total, but more than every five-year combination total from the years 2000 to 2014. It is an increase of 65% over 2015, 200% over 2016, 118% over 2017, 68% over 2018 and 95% over 2019. Both IPOs ($23.7 billion) and venture capital rounds ($37.8 billion) have hit all-time records this year. But will the onslaught of money continue for the industry?
Whether it’s the highly mutated Omicron variant emerging in South Africa as biopharma researchers scramble to create custom-made vaccines in record time or the institutional mandates juxtaposed with waning vaccine immunity and the ongoing ups and downs of cases and deaths, the SARS-CoV-2 virus continues to dig its ugly spikes into an uncertain and anxious world.
While the world grapples for a clear picture of the Omicron variant and how to handle it, Moderna Inc., Biontech SE and Adagio Therapeutics Inc. stepped out with stock advances, building on momentum from the end of last week, while eyeing 2022 as a launch date against the variant.
LONDON – Cases of the new variant of SARS-CoV-2, which has an unprecedented number of mutations in the spike protein that is the target of most COVID-19 vaccines, have now been reported across Europe and in Canada, following its initial detection in South Africa.
RSS
